| Předmět: |
|
| Zdroj: |
Women's Health Weekly; 2024, p2343-2343, 1p |
| Abstrakt: |
Minerva Biotechnologies Corporation has been issued a patent for humanized anti-MUC1 antibodies. These antibodies target a cleaved form of the MUC1 protein, which is a growth factor receptor found in over 75% of human cancers. The invention involves engineering recognition fragments of non-human antibodies into human antibodies, a process known as "humanizing." The patent also discusses the use of chimeric antigen receptor (CAR) therapy and bispecific T cell engagers (BiTEs) as cancer immunotherapies. The patent includes detailed claims for the chimeric antigen receptor and its components. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
